NEW YORK (GenomeWeb) – A team from the Netherlands, the UK, and the US has developed a so called "drug-tolerant assay" to track tumor necrosis factor (TNF) dynamics in rheumatoid arthritis patients treated with the monoclonal antibody adalimumab, a TNF inhibitor.

Using the test, they have garnered evidence that TNF concentrations in the blood do not necessarily reflect response to the drug.